Investment Analysts’ Weekly Ratings Updates for LivaNova (LIVN)

Several analysts have recently updated their ratings and price targets for LivaNova (NASDAQ: LIVN):

• 12/1/2025 – LivaNova had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – LivaNova had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – LivaNova had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – LivaNova had its price target raised by analysts at Robert W. Baird from $63.00 to $70.00. They now have an “outperform” rating on the stock.
• 11/13/2025 – LivaNova had its price target raised by analysts at Mizuho from $65.00 to $70.00. They now have an “outperform” rating on the stock.
• 11/6/2025 – LivaNova had its price target raised by analysts at Robert W. Baird from $61.00 to $63.00. They now have an “outperform” rating on the stock.
• 10/8/2025 – LivaNova had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.